Angiomics is a research and development company focused to improving vascular health. Using next-generation assays, the firm was involved in testing efficacy of materials and agents for use as therapies affecting blood vessel growth. principal of the firm has relocatd to Kenucky and is now Chief of the Division of Cardiovascular Therapeutics at the Cardiovascular Innovation Institute (CII) and a professor in the Department of Physiology & Biophysics, University of Kentucky.
